N/A N=9 Effects of Obesity Surgery on Renal Function
Impaired Renal Function
Primary: Changes in Glomerular Renal Function After Weight Loss Surgery as Measured by 51Cr-EDTA Clearance — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=80 Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs
Venous Thromboembolism
Primary: Incidence of Any Adjudicated Bleeding Events — 33.3; 14.3; 22.7; 40.0 percentage of subjects with bleeds
N/A N=428 Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
Arthroplasty, Replacement · Thromboembolism
Primary: Percentage of Patients With Major Bleeding Events (MBE) — 2.10 percentage of participants
Phase 4 N=442 Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.
Major Orthopaedic Surgery and Renal Impairment
Primary: Number of Patients With Major Bleedings Between Day 1 and Day 10. — 20 participants
N/A N=1,113 Renal Replacement Therapy and In-Hospital Mortality Incidence in Cardiac Surgery Associated Acute Kidney Injury
Acute Kidney Injury
Primary: Mortality — 96; 34 Participants — p=<0.0001
N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
Phase 2 N=49 Neuromuscular Blockade in Patients With Severe Renal Impairment
Neuromuscular Blockade · Renal Impairment
Primary: Time Until Complete Reversal of Neuromuscular Blockade — 14.8; 3.5 Minutes
Phase 3 N=210 Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes
Renal Cancer
Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to 6 Months — -8.5; -8.4 % change from preoperative eGFR
N/A N=120 Evaluate the Nephrotoxicity by 6% Hydroxyethyl Starch 130/0.4 in Old Patients During Orthopaedic Surgery
Total Fluid Volume Increased
Primary: Concentration of NGAL in Urine on 5 Time Point — 5.6; 4.9; 5.2; 5.1 ng/ml
Phase 2 N=44 Effectiveness of Minimally Invasive Total Knee Replacement in Improving Rehabilitation and Function
Osteoarthritis
Primary: Quadriceps Muscle Force — 1.27; 1.37; 0.79; 0.66 Nm/kg — p=0.07
N/A N=18 Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
Complication of Extracorporeal Circulation · Renal Impairment
Primary: Renal Blood Flow (RBF) — 554; 524; 564; 558 ml per minute per 1.73 m2 body surface — p=0.638
Phase 2 N=21 Tranexamic Acid Dosing for Major Joint Replacement Surgery
Arthroplasty, Replacement, Knee · Arthroplasty, Replacement, Hip
Primary: Blood Plasma TXA Concentration - Total Body Clearance — 58.0; 116 mL/min
N/A N=455 Safety of Total Knee Replacement Surgery Before and After the Implementation of Enhanced Recovery Program
Arthroplasty Complications
Primary: Number of Patients With Early Complication — 9; 16; 4 Participants
N/A N=150 Traditional vs Oral Fluid Management in Total Knee Arthroplasty
Arthroplasty, Replacement, Knee
Primary: Body Weight — -1.9; -1.6 pounds
N/A N=617 Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery
Acute Kidney Injury · Post-Operative Delirium · Icu Delirium
Primary: Number of Participants With Acute Kidney Injury — 64; 60 Participants — p=.75
N/A N=40 Minocycline to Prevent Acute Kidney Injury After Cardiac Surgery
Kidney Failure, Acute · Acute Kidney Insufficiency
Primary: Development of Post-operative Acute Kidney Injury — 10; 7 participants meeting primary oputcome
N/A N=150 Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
Venous Thromboembolism · Arthroplasty
Primary: Deep Vein Thrombosis — 0; 1 Participants
N/A N=10 A Biologic Joint Replacement Strategy to Treat Patients With Severe Knee Trauma and Post-Traumatic Knee Osteoarthritis
Post-traumatic Osteoarthritis
Primary: Visual Analogue Scale Pain Score — 2.3 units on a scale
N/A N=76 Home Rehabilitation in Patients After Primary Total Knee Arthroplasty
Osteoarthritis · Rehabilitation
Primary: Total WOMAC Score — 51.64285714; 52.47619048; 39.60714286; 40.38095238 score on a scale
N/A N=1,108 Using Alternative Implants for the Surgical Treatment of Hip Fractures (The FAITH Study)
Femoral Neck Fractures
Primary: Revision Surgery — 107; 117 Participants
Phase 2 N=42 Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.
Renal Transplant Osteodystrophy
Primary: Bone Mineral Density of Spine at 6 Months — 0.98; 0.97 gm/cm^2
Phase 4 N=30 Steroids in Bilateral Total Knee Replacement
Postoperative Inflammatory Response
Primary: Decrease in IL6 Level — 359.4; 381.6 pg/ml
N/A N=116 Perioperative Mental Health in Orthopedic Surgery
Orthopedic Surgery · Older Adults · Depression
Primary: PHQ-ADS (Patient Health Questionnaire Anxiety and Depression Scale) — 16.84; 19.35; 11.26; 13.09 Points
N/A N=60 Fluid and Nutrition in Elective Hip Surgery
Hip Surgery Corrective
Primary: Change in Insulin Sensitivity (Percent) — -43; -38; -51 percent change of insulin sensitivity
N/A N=141 Renal Osteodystrophy: An Individual Management Approach
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
N/A N=180 A Study on M2a Magnum Total Hip Arthroplasty
Degenerative Joint Disease · Avascular Necrosis
Primary: Range of Motion — 109.2; 110.2 degrees
Phase 2 N=110 Enoxaparin Metabolism in Reconstructive Surgery Patients
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolus
Primary: Number of Participants With Venous Thromboembolism Events — 5; 0 Participants
Phase 3 N=24 Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement
Arthropathy of Knee Joint
Primary: Vancomycin Concentration in Fat — 6.0; 40.5 ug/g — p=0.001
Phase 2 N=92 Prevention of Acute Kidney Injury in Cardiac Surgery Patients
Kidney Injury
Primary: Number of Participants With Acute Kidney Injury — 20; 14 participants
Phase 3 N=90 Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
Osteoporosis · Chronic Kidney Disease
Primary: Percent Change in BMD at the Total Lumbar Spine From Baseline to Month 12 — 4.5; -0.3 percent change — p=<0.001